查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1983803

感染疾病治療市場：2026-2032年全球市場預測（依藥物類別、給藥途徑、適應症、最終用戶和分銷管道分類）

Infectious Disease Therapeutics Market by Drug Class, Route Of Administration, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，感染疾病治療市場價值將達到 1,268 億美元，到 2026 年將成長至 1,325.9 億美元，到 2032 年將達到 1,831.3 億美元，複合年成長率為 5.39%。

主要市場統計數據
基準年 2025 1268億美元
預計年份：2026年 1325.9億美元
預測年份 2032 1831.3億美元
複合年成長率 (%) 5.39%

為感染疾病治療市場制定簡潔的策略框架，以增強相關人員對臨床創新、監管趨勢和營運重點的理解。

目前感染疾病治療正處於關鍵轉折點，這主要得益於分子生物學的進步、疫苗研發進程的加速以及日益複雜的全球供應鏈格局。本導言為研究、生產、臨床實踐和政策領域的相關人員提供了一個策略背景，重點闡述了科學創新與監管調整如何整合並影響短期決策。此外，本導言也確立了貫穿整個報告的分析觀點：一種將治療方法、給藥途徑和最終用戶實際情況與營運限制和商業性機會聯繫起來的綜合觀點。

技術進步、監管現代化和不斷變化的臨床需求如何重新定義感染疾病治療的開發路徑和商業化策略。

感染疾病治療領域正經歷變革性的轉變，這得益於技術突破、新的監管模式以及不斷變化的臨床需求。基因療法和生物製藥療法日趨成熟，單株抗體和細胞激素調變器不再只是治療工具，而是綜合治療方法中不可或缺的一部分。同時，能夠實現快速設計、迭代改進和適應性生產的疫苗技術平台正在重塑針對不同病原體的預防策略。這些技術進步伴隨著數位技術和診斷技術的進步，使得早期檢測和更具針對性的治療方法成為可能，從而改變了臨床路徑和支付方的考量。

對 2025 年關稅趨勢將如何重塑治療領域的供應鏈策略、採購決策和生產在地化進行全面分析。

2025年美國關稅政策發展的累積影響將重塑整個感染疾病治療生態系統的供應鏈經濟、採購行為和策略採購決策。關稅變化正直接影響活性成分、生物製藥以及商業生產和研發營運所需的試劑的成本。由此帶來的單位經濟效益壓力迫使製造商重新評估供應商多元化、庫存持有策略以及近岸外包方案，以降低進口相關成本波動帶來的風險。

透過提供將治療領域、給藥途徑、臨床適應症、分銷管道和最終用戶趨勢聯繫起來的綜合細分觀點，我們提供了確定優先事項所需的必要資訊。

細分市場分析揭示了產品、劑量和臨床用途的差異，這些差異從根本上改變了藥物的研發和商業化策略。從藥物類別（抗生素、抗真菌藥物、抗病毒藥物、生物製藥和疫苗）的角度來看，每一類藥物都面臨獨特的臨床和生產方面的考量。抗生素在各種亞類中都保持著重要性，包括Aminoglycosides、BETA-內醯胺類、Fluoroquinolones、大環內酯類和四環黴素，每種抗生素具有不同的抗藥性動態和合理用藥需求，這些都會影響臨床指南和採購偏好。抗真菌藥物，包括Azole、Echinocandins和Polyenes，面臨獨特的診斷和劑量複雜性，這影響它們在醫院處方集和門診治療中的應用。抗病毒藥物，例如整合酶抑制劑、神經氨酸酶抑制劑、核苷類似物和蛋白酶抑制劑，具有治療特異性和抗藥性，因此需要聯合用藥策略和用藥依從性干預措施。

美洲、歐洲、中東、非洲和亞太地區的監管多樣性、製造能力和醫療保健系統優先事項如何決定醫療服務取得和策略重點。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的監管時間表、生產策略和患者用藥途徑都產生了重大影響。在美洲，法規環境差異顯著，既有核准流程完善、高度集中的體系，也有可能延誤跨境用藥的分散式司法管轄結構。這種多樣性要求企業制定差異化的打入市場策略、策略性的價格談判以及確保持續供應的緊急時應對計畫。在歐洲、中東和非洲（EMEA）地區，相關人員必須應對複雜的監管方式、報銷框架和公共衛生優先事項。在此背景下，聯合採購機制和區域疾病負擔在部署曲線和公開競標中發揮著至關重要的作用。

關鍵競爭模式揭示了推動感染疾病治療領域成功的科學差異化、製造策略和夥伴關係模式。

感染疾病治療領域主要企業之間的競爭格局是由科學差異化、生產規模和夥伴關係彈性三者共同驅動的。成熟的跨國公司利用其龐大的產品線和全球生產網路，持續支援後期研發和大規模商業化部署；而規模較小的生物技術公司則往往專注於獨特的作用機制和適合許可和合作開發的平台技術。合約研發生產機構（CDMO）是生技藥品和疫苗生產的策略性促進者，它們提供柔軟性的生產能力和專業知識，並能縮短缺乏固定生產資產的申辦者進行臨床試驗的時間。

行業領導者應採取切實可行的高優先級措施，以增強其整個治療產品組合的供應韌性、證據生成和以患者為中心的市場進入。

產業領導者應採取一系列優先且切實可行的措施，以應對不斷變化的科學、監管和供應鏈環境。首先，企業需要將供應鏈韌性作為核心策略目標，具體措施包括供應商多元化、尋求區域性生產方案以及正式建立緊急儲備。這些措施將有助於降低貿易政策衝擊帶來的風險，並保障醫療服務的連續性。其次，將真實世界資料（REW）收集融入產品上市和上市後活動中，將有助於加快支付方的接受度，並支持靈活的監管路徑。因此，各機構應投資於數位資料收集工具和跨相關人員的證據夥伴關係，以確保獲得高品質的長期結果資料。

採用透明、多方面的研究途徑，結合專家訪談、對二手證據進行三角檢驗和檢驗程序，確保研究結果的實用性和可重複性。

本分析的調查方法透過整合多源證據、與相關專家合作以及嚴格的檢驗通訊協定，確保了研究結果的穩健性和相關性。關鍵投入包括對臨床醫生、供應鏈高管、監管專家和銷售主管進行結構化訪談，以收集有關臨床實踐、採購決策和生產策略的一線觀點。這些質性見解與同儕審查的臨床文獻、公開的監管指導文件和企業資訊披露等二手資料進行交叉比對，從而建立基於事實的治療方法特徵和監管趨勢標準。

透過整合強調韌性、實證市場進入和營運協調的策略挑戰，我們加快部署速度並改善患者預後。

總之，感染疾病治療正受到多種複雜因素的共同影響而重塑，這些因素包括快速的科學創新、不斷變化的監管預期以及因關稅調整等政策變化而加劇的供應鏈現狀。這些趨勢要求整個價值鏈上的相關人員——包括研發者、製造商、支付者和醫療保健系統——採取整合策略，將科學差異化與營運韌性相結合。本報告提出的細分框架揭示了治療特性、給藥途徑、臨床適應症和分銷管道的交匯點，這些交匯點帶來了獨特的策略挑戰。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：感染疾病治療藥物市場：依藥物類別分類

  • 抗生素
    • Aminoglycosides
    • BETA-內醯胺
    • Fluoroquinolones
    • 大環內酯類
    • 四環黴素
  • 抗真菌藥物
    • Azole
    • Echinocandins
    • Polyenes
  • 抗病毒藥物
    • 整合酶抑制劑
    • 神經氨酸酶抑制劑
    • 核苷類似物
    • 蛋白酶抑制劑
  • 生物製藥
    • 細胞激素
    • 單株抗體
  • 疫苗
    • 組合型
    • 失活
    • 活病毒疫苗
    • 次單元

第9章：感染疾病治療藥物市場：依給藥途徑分類

  • 吸入
  • 靜脈
  • 口服
  • 外用

第10章：感染疾病治療市場：依適應症分類

  • COVID-19
  • 胃腸道感染疾病
  • 肝炎
  • 愛滋病毒/愛滋病
  • 呼吸道感染疾病
  • 皮膚感染疾病
  • 尿道感染

第11章：感染疾病治療市場：依最終用戶分類

  • 診所
  • 居家醫療
  • 醫院

第12章：感染疾病治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：感染疾病治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：感染疾病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：感染疾病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國感染疾病治療藥物市場

第17章：中國感染疾病治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Allergan PLC
  • Amgen Inc.
  • Astellas Pharma US, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioCryst Pharmaceuticals, Inc.
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Chimerix, Inc.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Chemical Group Corporation
  • Mylan NV
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.
Product Code: MRR-F6513A06BE17

The Infectious Disease Therapeutics Market was valued at USD 126.80 billion in 2025 and is projected to grow to USD 132.59 billion in 2026, with a CAGR of 5.39%, reaching USD 183.13 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 126.80 billion
Estimated Year [2026] USD 132.59 billion
Forecast Year [2032] USD 183.13 billion
CAGR (%) 5.39%

Concise strategic framing of the infectious disease therapeutics environment to orient stakeholders around clinical innovation, regulatory dynamics, and operational priorities

The infectious disease therapeutics landscape is at a pivotal inflection point driven by advances in molecular biology, accelerated vaccine development pathways, and an increasingly complex global supply environment. This introduction frames the strategic context for stakeholders across research, manufacturing, clinical practice, and policy, emphasizing the confluence of scientific innovation and regulatory adaptation that shapes near-term decisions. It establishes the analytical lens used throughout this report: an integrated view that links therapeutic modality, route of administration, and end-user realities to operational constraints and commercial opportunity.

In the following sections, the reader will encounter assessments of market dynamics, policy shocks, and segmentation-specific implications that collectively inform high-priority actions. The narrative prioritizes translational considerations: how pipeline innovations move from lab to clinic, how manufacturing resilience influences product availability, and how distribution channels modulate access at the point of care. By synthesizing technical, regulatory, and commercial vectors, this introduction prepares the reader to interpret downstream chapters with a focus on practical implications for investment, partnership, and operational planning.

How converging technological advances, regulatory modernization, and shifting clinical demand are redefining development pathways and commercialization strategies for infectious disease therapies

Transformative shifts in infectious disease therapeutics are unfolding through technological breakthroughs, novel regulatory paradigms, and shifting patterns of clinical demand. Gene-based and biologic approaches have matured to the point where monoclonal antibodies and cytokine modulators are not only therapeutic tools but also essential components of integrated treatment regimens. Concurrently, vaccine technology platforms that enable rapid design, iterative improvements, and adaptive manufacturing are reshaping prevention strategies across diverse pathogen classes. These technical developments are accompanied by digital and diagnostic advances that allow for earlier detection and more targeted therapy selection, thereby altering clinical pathways and payer considerations.

Beyond science, regulatory agencies have adopted more flexible review mechanisms and emergency-use frameworks that, while expediting access, require sponsors to engage in more continuous post-market evidence generation. As a result, commercialization strategies increasingly require lifecycle planning that balances accelerated entry with robust real-world evidence programs. In parallel, health systems are recalibrating procurement and formularies to favor products that demonstrate not only clinical efficacy but also demonstrable supply resilience and affordability. Taken together, these shifts demand that companies re-architect R&D pipelines, manufacturing footprints, and market access approaches to remain competitive and responsive to rapidly evolving clinical needs.

Comprehensive analysis of how 2025 tariff developments are recalibrating supply chain strategies, procurement decisions, and manufacturing localization across therapeutics

The cumulative effects of United States tariff policy developments in 2025 are shaping supply-chain economics, procurement behaviors, and strategic sourcing decisions across the infectious disease therapeutics ecosystem. Tariff changes have had a direct bearing on the cost of active pharmaceutical ingredients, certain biologics inputs, and reagents critical to both commercial manufacturing and research operations. The resulting pressure on unit economics has compelled manufacturers to revisit supplier diversification, inventory stocking policies, and nearshoring alternatives to mitigate exposure to import-related cost volatility.

In response, forward-looking organizations have accelerated investments in localized manufacturing capabilities and strategic partnerships with contract development and manufacturing organizations that offer regional resiliency. These moves are intended to insulate production from tariff-induced margin erosion while preserving speed-to-market for high-priority products. Additionally, procurement teams have adopted more granular cost-control measures, renegotiating long-term contracts and applying total landed cost analysis rather than price-per-unit alone. Regulatory and reimbursement stakeholders have likewise taken notice: payers are scrutinizing cost drivers more closely, and health systems are incorporating supply-chain risk assessments into formulary decisions.

Finally, the tariff environment has amplified the importance of policy engagement. Industry participants are increasingly proactive in articulating the downstream clinical and public-health implications of trade measures, aiming to inform adjustments that preserve patient access and maintain manufacturing competitiveness. Overall, the 2025 tariff context has not only reallocated cost burdens but also catalyzed structural shifts in sourcing, manufacturing strategy, and stakeholder alignment across the therapeutic value chain.

Integrated segmentation perspective connecting therapeutic class, administration route, clinical indication, distribution channel, and end-user dynamics to inform prioritization

Segmentation analysis illuminates product, administration, and clinical-use distinctions that fundamentally alter development and commercialization approaches. When viewed through drug class lenses such as antibiotics, antifungals, antivirals, biologics, and vaccines, each category presents unique clinical and manufacturing considerations. Antibiotics retain importance across diverse sub-classes including aminoglycosides, beta-lactams, fluoroquinolones, macrolides, and tetracyclines, each with differing resistance dynamics and stewardship imperatives that influence clinical guidelines and procurement preferences. Antifungal therapies, encompassing azoles, echinocandins, and polyenes, face distinct diagnostics and dosing complexities that shape hospital formulary uptake and outpatient treatment pathways. Antiviral agents such as integrase inhibitors, neuraminidase inhibitors, nucleoside analogues, and protease inhibitors exhibit therapeutic specificity and resistance profiles that drive combination strategies and adherence interventions.

Biologics, including cytokines and monoclonal antibodies, require sophisticated cold-chain logistics and manufacturing control strategies that differentiate them from small-molecule agents, while vaccine types such as conjugate, inactivated, live attenuated, and subunit platforms each demand tailored manufacturing footprints, cold-chain requirements, and regulatory dossiers. Route of administration is a pivotal segmentation axis: inhalation, intravenous, oral, and topical modalities affect patient adherence, site-of-care economics, and distribution channel suitability. Indication-specific segmentation further refines strategic choices; therapeutic focus areas such as COVID-19, gastrointestinal infections, hepatitis, HIV/AIDS, respiratory infections, skin infections, and urinary tract infections create distinct clinical trial designs, real-world evidence needs, and payer conversations. Distribution channel distinctions among hospital pharmacy, online pharmacy, and retail pharmacy shape fulfillment models and post-market surveillance pathways, while end-user segmentation - clinics, homecare, and hospitals - determines service delivery models, capacity planning, and support-service requirements.

Bringing these segmentation dimensions together enables stakeholders to identify where clinical unmet needs intersect with advantageous product characteristics, where manufacturing complexity aligns with reimbursement potential, and where route-of-administration innovations can unlock new access pathways. This integrated segmentation perspective supports more precise prioritization of portfolio investments, targeted engagement with clinical and payer stakeholders, and optimized distribution strategies that reflect distinct use-case realities.

How regional regulatory diversity, manufacturing capacity, and health-system priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific determine access and strategic focus

Regional dynamics exert a material influence on regulatory timelines, manufacturing strategy, and patient access across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, regulatory environments vary from highly centralized systems with robust approval pathways to fragmented jurisdictional landscapes that can slow cross-border access; this diversity necessitates differentiated market-entry tactics, strategic pricing discussions, and contingency plans for supply continuity. In the Europe Middle East & Africa context, stakeholders must navigate a mosaic of regulatory approaches, reimbursement frameworks, and public-health priorities, where collaborative procurement mechanisms and regional disease burden profiles play a significant role in adoption curves and public tenders.

Asia-Pacific presents a dynamic mix of established and rapidly evolving markets, with strong local manufacturing capacity in several economies and growing demand for both advanced biologics and accessible small-molecule therapies. Policy drivers in this region often prioritize self-reliance in critical medicines, fostering investment in domestic production and technology transfer. Across regions, differences in health-system funding mechanisms, public-health priorities, and logistical constraints shape where investment in cold-chain infrastructure, point-of-care diagnostics, and decentralized delivery models will yield the greatest returns. Importantly, regional regulatory harmonization efforts and multilateral procurement initiatives have the potential to lower barriers to entry for innovative therapies, provided that sponsors align dossiers and evidence-generation strategies to meet cross-jurisdictional requirements.

Key competitive patterns revealing how scientific differentiation, manufacturing strategy, and partnership models drive success in infectious disease therapeutics

Competitive dynamics among leading companies in infectious disease therapeutics are driven by a combination of scientific differentiation, manufacturing scale, and partnership agility. Established multinational firms continue to leverage deep pipelines and global manufacturing networks to support late-stage development and broad commercial launches, while smaller biotechnology companies often focus on niche mechanisms of action or platform technologies that can be licensed or co-developed. Contract development and manufacturing organizations have become strategic enablers, offering flexibility in capacity and specialized know-how for biologic and vaccine production, which accelerates time-to-clinic for sponsors without fixed manufacturing assets.

Across the landscape, successful companies deploy a mix of business models: some prioritize vertically integrated control over manufacturing to ensure supply resilience, while others pursue asset-light approaches that emphasize speed and portfolio breadth through external partnerships. Digital capabilities-ranging from advanced analytics for pharmacovigilance to remote patient monitoring and adherence platforms-are increasingly used to differentiate commercial propositions and support payer dialogues. Strategic alliances between therapeutic developers, diagnostic firms, and distribution partners are also more common, reflecting a recognition that bundled solutions can improve clinical outcomes and simplify procurement for health systems. In sum, the competitive landscape rewards organizations that combine scientific rigor with operational adaptability and collaborative go-to-market strategies.

Practical high-priority actions for industry leaders to strengthen supply resilience, evidence generation, and patient-centric market access across therapeutic portfolios

Industry leaders should adopt a set of prioritized, actionable measures to navigate evolving scientific, regulatory, and supply-chain realities. First, companies must embed supply resilience as a core strategic objective by diversifying supplier bases, pursuing regional manufacturing options, and formalizing contingency inventories; such measures reduce exposure to trade-policy shocks and maintain continuity of care. Second, integrating real-world evidence generation into launch and post-marketing activities will accelerate payer acceptance and support adaptive regulatory pathways, so organizations should invest in digital data capture tools and cross-stakeholder evidence partnerships to ensure high-quality, longitudinal outcome data.

Third, commercial strategies must increasingly account for route-of-administration and end-user preferences; developing patient-centric formulations or delivery options that enable homecare and outpatient treatment can shift utilization patterns in a way that benefits both patients and payers. Fourth, strategic partnerships with contract manufacturers, diagnostics firms, and regional distributors should be pursued proactively to manage capacity constraints and streamline market access. Finally, companies should prioritize transparent engagement with policymakers and procurement bodies to communicate clinical value and the implications of trade or tariff policies on access. Collectively, these actions balance short-term operational imperatives with long-term value creation and resilience.

Transparent multi-method research approach combining expert interviews, secondary evidence triangulation, and validation procedures to ensure actionable and reproducible insights

The research methodology underpinning this analysis combined multi-source evidence synthesis, targeted expert engagement, and rigorous validation protocols to ensure robustness and relevance. Primary inputs included structured interviews with clinicians, supply-chain executives, regulatory specialists, and commercial leaders to capture first-hand perspectives on clinical practice, procurement decision-making, and manufacturing strategy. These qualitative insights were triangulated with secondary source materials such as peer-reviewed clinical literature, publicly available regulatory guidance documents, and company disclosures to establish a factual baseline for therapeutic modality characteristics and regulatory trends.

To ensure analytical rigor, findings were cross-validated through iterative consultations with subject-matter experts and technical reviewers who assessed assumptions about clinical adoption, manufacturing complexity, and distribution logistics. Data quality controls included source provenance checks, conflict-of-interest screening for interview participants, and an audit trail documenting how primary and secondary inputs informed each analytical conclusion. The methodology emphasizes transparency and reproducibility; detailed appendices provide interview protocols, inclusion criteria for secondary sources, and definitions for segmentation axes so that readers can evaluate the basis for strategic recommendations and adapt insights to their own operational contexts.

Synthesis of strategic imperatives emphasizing resilience, evidence-driven market access, and operational alignment to accelerate adoption and improve patient outcomes

In conclusion, infectious disease therapeutics are being reshaped by intersecting forces: rapid scientific innovation, evolving regulatory expectations, and supply-chain realities intensified by policy shifts such as tariff adjustments. These dynamics demand that stakeholders across the value chain-developers, manufacturers, payers, and health systems-adopt integrated strategies that align scientific differentiation with operational resilience. The segmentation framework presented in this report clarifies where therapeutic characteristics, administration routes, clinical indications, and distribution channels converge to create distinct strategic imperatives.

Looking ahead, success will favor organizations that can translate technical innovations into scalable production and delivery models while maintaining flexible, evidence-driven approaches to market access. Proactive engagement with regulatory and procurement stakeholders, targeted investments in manufacturing and data infrastructure, and creative partnership models will be central to sustaining competitive advantage. The synthesis provided here is intended to support informed decision-making by highlighting where effort and capital can most effectively reduce risk, accelerate adoption, and ultimately improve patient outcomes across diverse infectious disease priorities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Infectious Disease Therapeutics Market, by Drug Class

  • 8.1. Antibiotics
    • 8.1.1. Aminoglycosides
    • 8.1.2. Beta Lactams
    • 8.1.3. Fluoroquinolones
    • 8.1.4. Macrolides
    • 8.1.5. Tetracyclines
  • 8.2. Antifungals
    • 8.2.1. Azoles
    • 8.2.2. Echinocandins
    • 8.2.3. Polyenes
  • 8.3. Antivirals
    • 8.3.1. Integrase Inhibitors
    • 8.3.2. Neuraminidase Inhibitors
    • 8.3.3. Nucleoside Analogues
    • 8.3.4. Protease Inhibitors
  • 8.4. Biologics
    • 8.4.1. Cytokines
    • 8.4.2. Monoclonal Antibodies
  • 8.5. Vaccines
    • 8.5.1. Conjugate
    • 8.5.2. Inactivated
    • 8.5.3. Live Attenuated
    • 8.5.4. Subunit

9. Infectious Disease Therapeutics Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Topical

10. Infectious Disease Therapeutics Market, by Indication

  • 10.1. COVID-19
  • 10.2. Gastrointestinal Infections
  • 10.3. Hepatitis
  • 10.4. HIV/AIDS
  • 10.5. Respiratory Infections
  • 10.6. Skin Infections
  • 10.7. Urinary Tract Infections

11. Infectious Disease Therapeutics Market, by End User

  • 11.1. Clinics
  • 11.2. Homecare
  • 11.3. Hospitals

12. Infectious Disease Therapeutics Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Infectious Disease Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Infectious Disease Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Infectious Disease Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Infectious Disease Therapeutics Market

17. China Infectious Disease Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Alexion Pharmaceuticals, Inc.
  • 18.7. Allergan PLC
  • 18.8. Amgen Inc.
  • 18.9. Astellas Pharma US, Inc.
  • 18.10. AstraZeneca PLC
  • 18.11. Bayer AG
  • 18.12. BioCryst Pharmaceuticals, Inc.
  • 18.13. Biogen Inc.
  • 18.14. Boehringer Ingelheim GmbH
  • 18.15. Bristol-Myers Squibb Company
  • 18.16. Celgene Corporation
  • 18.17. Chimerix, Inc.
  • 18.18. Eli Lilly and Company
  • 18.19. Gilead Sciences, Inc.
  • 18.20. GlaxoSmithKline PLC
  • 18.21. Johnson & Johnson Services, Inc.
  • 18.22. Merck & Co., Inc.
  • 18.23. Mitsubishi Chemical Group Corporation
  • 18.24. Mylan N.V.
  • 18.25. Novartis AG
  • 18.26. Novo Nordisk A/S
  • 18.27. Pfizer Inc.
  • 18.28. Sanofi S.A.
  • 18.29. Takeda Pharmaceutical Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COVID-19, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV/AIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SKIN INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 236. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 237. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 238. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 239. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 240. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 242. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. GCC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 268. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 269. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 270. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 271. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 272. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 273. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 275. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. G7 INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 279. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 280. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 281. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 282. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 283. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 284. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 285. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 286. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. NATO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 288. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. U